A B S T R A C T Platelet Factor VIII-related antigen (VIIIR:Ag) represents a significant proportion of the total circulating VIIIR:Ag pool. However, its participation in the events of primary hemostasis has not been shown. We now report that platelet-contained VIIIR:Ag is released from platelets by collagen, ADP and thrombin. The concentrations of these agonists, required for VIIIR:Ag release, are the same or lower than those required for release of serotonin, lysosomal enzymes, or fibrinogen. This release has the features of an energydependent secretory response because it is blocked by the metabolic inhibitors, antimycin A and 2-deoxy-D-glucose. The electrophoretic characteristics of the VIIIR:Ag released by collagen and ADP are similar to those of plasma VIIIR:Ag. However, thrombin-released platelet VIIIR:Ag differs from that of plasma in that the less anodal forms are relatively depleted. These differences do not appear to be the result of proteolytic degradation of platelet-derived VIIIR:Ag, but may reflect interactions between specific molecular forms of VIIIR:Ag and the platelet membrane. These studies sug-
INTRODUCTION
Factor VIII-related antigen (VIIIR:Ag)l is a protein that appears to be necessary for normal platelet function. In von Willebrand's disease, this protein is either markedly decreased in the plasma (1) or is qualitatively abnormal (2) . These defects are associated with a prolonged bleeding time and decreased ristocetin-induced platelet aggregation (3) . Experimentally, VIIIR:Ag deficiency has been correlated with a decreased adhesion of platelets to subendothelium (4) . In plasma, VIIIR:Ag is also associated with the Factor VIII procoagulant activity (VIIIR:C), although the precise relationship between the two remains unclear. VIIIR:Ag has also been demonstrated in platelets (5-10), megakaryocytes (11, 12) , and the endothelial cell (11, 13) .
The platelet contains 10-15% of the total circulating VIIIR:Ag (5, 6) . Although VIIIR:Ag is synthesized in both the endothelial cell (14) and the megakaryocyte (15) , little is known about the physiology of cellular VIIIR:Ag, and no functional role has been demonstrated for it. We report here that a significant proportion ofplatelet VIIIR:Ag is released by stimulation with three physiologic agonists: ADP, collagen, and thrombin. This release has the features of a true secretory process because it is prevented by agents that inhibit energydependent functions by depleting the platelet metabolic pool of ATP. The kinetic features of VIIIR:Ag secretion by platelets in response to graded doses ofcollagen 'Abbreviations used in this paper: LDH, lactic dehydrogenase; 5HT, 5-hydroxytryptamine (serotonin); VIIIR:Ag, Factor VIII-related antigen; VIIIR:C, Factor VIII procoagulant activity; VIIIR:RCo, platelet-ristocetin cofactor activity.
J. Clin. Invest or thrombin are distinct from those of 5-hydroxytryptamine (5HT) (a dense body marker) or lysosomal enizymle (a-granule marker) secretion. The maximum amount of VIIIR:Ag releasable by thrombin is significantly less than is releasable by collagen. Moreover, the electrophoretic characteristics of VIIIR:Ag released into the supernate by platelets in respoinse to ADP or collagen are different from those of VIIIR:Ag released in response to thrombin.
METHODS
Preparationi of washed platelets. 9 vol of blood were collected by aseptic venipuncture with a 16-gauge needle and catheter into 1 vol of3.8% wt/vol trisodium citrate using plastic equipment and containers throughout. Platelet-rich plasma was obtained by centrifuigatioin at 300 g for 15 min. Plateletrich plasma was incubated with 0.5 ,uCi [2-14C]5HT binoxolate (New England Nuclear, Boston, Nlass.) per 20 ml for 40 miii at 37°C. Platelets were then washed twice by albumin density gratient separation at ph 6.5 in a calcium-free Tyrode's solution composed of: NaCl (8.0 g/liter), KCl (0.2 g/liter), NaH2PO4 2H2O (0.065 g/liter), MgCl2 6H20 (0.415 g/liter), NaHCO3 (1.0 g/ liter), dextrose (1.0 g/liter), and bovine serum albumin (1.0 g/liter; Sigma Chemical Co., St. Louis, Mo.) as described (16) with the exception that apyrase was not used. Platelets for ADP stimulation were taken directly from the second albumin gradient and diluted with 3 vol of calcium-free Tyrode's solution (pH 7.4) and 1 vol of citrated plasma obtained from a patient with severe (homozygous) von Willebrand's disease which contained <0.0005 U VIIIR:Ag/ml. For all other studies, after albumin density gradient washing, the platelets were gel filtered on a 25 x 1.6-cm column of Sepharose 2B (Pharmacia Fine Chemicals, Uppsala, Sweden) in the calcium-free Tyrode's solution at pH 7.4. Platelets were counted electronically with a model Z particle counter (Coulter Electronics, Inc., Hialeah, Fla.). This technique gave final platelet counts between 5.5 x 108 and 8.0 x 108 platelets/ml.
Experimlents twith wcashed platelets. Imipramine (CibaGeigy Corp., Pharmaceuticals Div., Summit, N. J.) was added to washed platelet suspensions at a final concentration of 5
ANl. This concentration has been determined to inhibit over 90% of the uptake of 5HT by platelets. Where metabolic inhibitor studies were performed, the washed platelets were incubated with a final concentration of 4 (18, 19 ) from a stock solution of 5 mg/nml in 0.01 M Tris, 0.14 NI sodium chloride, pH 7.4, and highly purified a-thrombin, prepared and handled as described (20) , in a stock solution of 9,000 I U/mnl in 0.75 M NaCl and kept at -70°C. All dilutions of these reagents were made with calcium-free Tyrode's solution, pH 7.4. Aggregation was performed by adding a 10% vol aliquot of the aggregating agent to a continiuously stirred (750 rpm) suspension of platelets in siliconized aggregometer cuvettes at 37°C. The stirring was conitinued for exactly 90 s in all cases and then the platelets were allowed to stand at 370C. For the dose-response studies, the period of reaction was terminated by ceintrifugation at 7,000 g for 2 min. For the majoritv of time-course studies, the reactions were terminated bv the addition of 5% by volume of a solution of formalin (0.4 MI) and EDTA (0.06 M) giving final concentrations of 20 mMI formnalin and 3 mM1 EDTA (21) . Matched studies determiine(d that the addition of formalin-EDTA did not significantl1 affect the assay' of VIIIR:Ag, 5HT, N-acetyl-,8-Dglucosamidase ora-glucuronidase, but did affect the measurement of fibrinogen. For this reason, time-course studies inv'olving fibrinogen release were terminated by centrifugation only. Time points of <5 min are therefore not given in these studies. In all studies, aggregation cuvettes were centrifuged at 7,000 g for 2 mni at room temperature, the supernate was removed and then recentrifuged at 7,000 g for an additional 10 min at 4°C. The superinate was then collected and immediately stored at 4°C. Platelets were lysed either by freeze-thawing in liquid nitrogeni four times, or by the addition of a 10% vol of a 10% solution of Triton X-100 (J. T. Baker Chemical Co., Phillipsburg, N. J. A number of studies were performed to determine if thrombin, or a substance released from platelets by thrombin, affected VIIIR:Ag, either quantitatively or qualitatively. Thrombin (0.5 U/ml, final concenitration) was added to the supernate of platelets 1 h after their stimulation by collagen (50 ,g/ml, final conceintration). Alternatively, highly purified VIIIR:Ag (0.04 U/ml, final concentration) of relatively slow electrophoretic mobility obtained from an early void volume fraction (22) was added to the supernate of platelets obtained 3 and 60 min after stimulation with thrombin or after freezethaw lysis. After incubation for an additional hour, the VIIIR:Ag of each sample was compared with the untreated material for any evidence of alteration in amount or electrophoretic mobility.
Timne-course studies. Reactions were stopped by the addition of formalin EDTA at 10, 30, 60, 120 s, 5, 20, 45, and 60 min. The zero-time control for these experiments was a platelet suspension to which the appropriate stimulus was added 10 s after the formalin-EDTA and allowed to incubate for 60 mmin. hrombin was used in a final concentration of 0.5 U/ml, collagen at 50 jig/ml, and ADP at 50 ,uM. Five time-course studies were performed with each agent. In three of these studies, metabolically inhibited platelets were studied concurrently.
Radio-crossed imm mnunoelectrophoresis and radio-quamstitated iunmunoelectrophoresis. These techniques were performed as described previouisly (23, 24) with the exception that 1251 affinity purified rabbit anti-VIIIR:Ag was mixed with unlabeled "native" rabbit anti-VIIIR:Ag and immunoprecipitates were detected with autoradiography instead of Coomassie Blue staining. This allowed the use of more dilute antibody and hence increased the sensitivity of these techniques. (As little as 0.0005 U of VIIIR:Ag could be detected.) Affinity purification of the rabbit anti-VIIIR:Ag was carried out as described elsewhere (25, 26 ). An immunoglobulin (Ig)G fractioni of high titer monospecific anti-VIIIR:Ag antisera (22) was prepared by ammonium sulfate fractionation and DEAE chromatography. This IgG was then applied to partially purified VIIIR:Ag (250 ,ug, 25 U) which had been cross-linked to 1 ml agarose by gluteraldehyde (25, 26) . The partially purified VIIIR:Ag was obtained by agarose gel chromatography of a commercial Factor VIII preparation. 250 iLg of rabbit antibody bound to these beads and 100 ,ug could be subsequently eluted at pH 2.2. This affinity purified antibody was labeled by the chloramine T technique to a sp act = 5 ,uCi 125I/;Lg (27) . The affinity purified antibody was monospecific detecting only VIIIR:Ag as analyzed in crossed immunoelectrophoresis of plasma or platelet protein (Figs. 5 and 6) or Ouchterlony analysis. It did not detect von Willebrand's disease antigen II (22) . In the radio crossed immunoelectrophoresis studies 50-pl samples were used with VIIIR:Ag concentrations varying from 0.025 to 0.15 U/ml. Freeze-thawing or Triton X-100 treatment of plasma VIIIR:Ag did not affect its appearance on radio-crossed immunoelectrophoresis or its quantitation by radio quantitative immunoelectrophoresis.
VIIIR:C was measured by a partial thromboplastin time technique (28) and platelet-ristocetin cofactor activity (VIIIR: RCo) by a tilt tube technique with fixed platelets (29) .
The lysosomal enzymes, 13-glucuronidase and N-acetyl-f3-glucosaminidase were assayed in the supernate of aggregated platelets by techniques described elsewhere (30, 31) . Lactic dehydrogenase (LDH) was measured in the supemate to detect cytoplasmic leakage as a result of platelet lysis. The assay was performed by a DuPont ACA (Automatic Chemical Analyzer), DuPont Instruments, Wilmington, Del., according to the manufacturer's instruction. 5HT release was measured by adding 0.03 ml supernate to 10 ml Aquasol (New England Nuclear) and counting the radioactivity in a liquid scintillation counter (Beckman LS 3133P; Beckman Instruments, Inc., Palo Alto, Calif.).
Fibrinogen quantitation. Fibrinogen released from the platelet was determined by a radioimmunoasay of the double antibody type as described (32, 33 Ag/Iml. This patient had a lifelong history ofexcessive bleeding and had a skin bleeding time of >20 min (normal = <8.5 min). The plasma level of VIIIR:Ag was 0.25 U/ml, VIIIR:C was 0.37 U/ml, and VIIIR:RCo was 0.15 U/ml.
RESULTS
Platelets washed by albumin density gradient and gel filtration were obtained in a final concentration of between 5.5 and 8 x 108 platelets/ml. Contaminating VIIIR:Ag in the supernate was <0.0005 U/ml and none was detectable throughout the course of the experiments unless stimulating agents were added. The washed platelets did not aggregate with ristocetin in the absence ofadded VIIIR:Ag. Total platelet VIIIR:Ag was determined by measuring the VIIIR:Ag released into the supemate after lysis of the platelets with 1% Triton X-100 for 1 h at 370C. Eight platelet preparations from different donors gave a total platelet VIIIR:Ag content of 0.17 U (SE+0.01)/5 x 108 platelets. Triton X-100 lysis of five separate preparations of washed platelets from the same donor gave a total platelet VIIIR:Ag content of 0.15 U (SE+±0.004)/5 x 108 platelets. Lysis of platelets with the freeze-thaw technique gave an average total platelet content 10% less than obtained with Triton X-100.
Collagen studies. Significant release of VIIIR:Ag was detected at a concentration of collagen of 5 Zg/ ml and maximum release was always obtained with 50 gg (Fig. 1) . Maximum release of VIIIR:Ag occurred at significantly lower concentrations of collagen than was necessary for maximum release of 5HT and the lysosomal enzymes. The maximum release ofeach component studied at 10 min after collagen stimulation, as a percentage of the total platelet content of each was: VIIIR:Ag, 26% (SEt3); 5HT, 80% (SE±5); Nacetyl-,f-D-glucosaminidase, 32% (SE ±3); j3-glucuronidase, 22% (SE+±2). No significant LDH was released during the course of any study reported here. In the 60-min incubation studies, no additional significant 5HT or lysosomal enzyme release was detected, but the maximum amount of VIIIR:Ag released increased to 50% (SE+±6) of the total platelet content. However; the concentration of collagen required to give maximum VIIIR:Ag release did not differ significantly between the 10-and 60-min studies (Fig. 2) .
The time-course of VIIIR:Ag release was studied over a period of 1 h with collagen at concentrations of 50 ug/ml (Fig. 3) . Almost 50% of the release of VIIIR:Ag was accomplished within 5 min. The release of 5HT and N-acetyl-,3-D-glucosaminidase (the latter not shown in Fig. 3 ) was even more rapid; both reaching an apparent maximum within 5 min. However, both 5HT and lysosomal enzyme release also appeared to show some progressive diminution of release rate with time, but the rate was so rapid that it was difficult to define the course with the same accuracy and clarity as could be obtained with VIIIR:Ag release.
In combination, antimycin A and 2-deoxy-D-glucosereduced collagen-induced release of VIIIR:Ag by 90% e 100- or more. Lysosomal enzyme release was completely inhibited and 5HT release was reduced to _50% of the normal response (Figs. 2 and 3) . Thrombin studies. Significant release of VIIIR:Ag was regularly detected at 0.025 U/ml thrombin and maximum release was always obtained at 0.5 U/ml thrombin. The dose-response curve of VIIIR:Ag release in response to thrombin was not significantly different to that of 5HT release, but both were different from the thrombin-induced dose response of lysosomal enzyme release from the platelets (Fig. 4) . Maximum release of VIIIR:Ag after incubation periods of 10 and 60 min was achieved at the same thrombin concentration. Five experiments were performed, including three in which washed platelets were incubated at 37°C for 30 Thus, although the absolute amount of VIIIR:Ag increased between these two time points, it did so proportionately at all thrombin concentrations. The maximum amount of VIIIR:Ag released by thrombin (33% of the total platelet VIIIR:Ag) was lower than for collagen, although more 5HT and N-acetyl-,f-glucosaminidase were released by thrombin (Table I) . In seven experiments, in which both collagen-and thrombininduced release were studied simultaneously over an incubation period of 1 h, the thrombin-induced maximum release was 59% (SE +6) ofthe maximum VIIIR:Ag released by collagen. Time-course studies of release of 5HT and VIIIR:Ag by thrombin (0.5 U/ml) gave essentially identical results to those obtained with collagen (Fig. 5) . Release was most rapid initially with almost 50% of the release of VIIIR:Ag being accomplished within 5 min.
The metabolic inhibitors, antimycin A and 2-deoxy-1-glucose, significantly inhibited thrombin-induced 5HT, lysosomal enzyme and VIIIR:Ag release. As with collagen-induced release, VIIIR:Ag release was more markedly inhibited than 5HT release at these concentrations of inhibitors (Fig. 5) Crossed immunoelectrophoresis analyses of platelet VIIIR:AG. Crossed immunoelectrophoresis showed consistent differences between the VIIIR:Ag released by collagen and ADP as compared to thrombin (Fig. 6 ). Collagen and ADP-released VIIIR:Ag had electrophoretic characteristics similar to plasma VIIIR:Ag. Thrombin-released VIIIR:Ag, on the other hand, was depleted of the less anodal (slower) migrating forms with only the more anodal (faster) migrating forms found in plasma being present.
There was also less obvious, but consistent, differences between the VIIIR:Ag obtained by Triton X-100 and freeze-thaw lysis and plasma. Triton X-100 lysed platelets released relatively more of the slower migrating forms of VIIIR:Ag as compared to plasma, whereas freeze-thaw lysed platelets released VIIIR:Ag which was relatively depleted of these forms as compared to plasma (or collagen and ADP-released VIIIR:Ag). The addition of thrombin to collagen-released VIIIR:Ag, or of highly purified VIIIR:Ag to the supemate of thrombin-stimulated platelets and freeze-thaw lysed platelets, caused no detectable quantitative or qualitative alteration of VIIIR:Ag.
Platelet VIIIR:Ag in von Willebrand's disease. The platelets from a patient with von Willebrand's disease whose plasma lacked the slower migrating forms of VIIIR:Ag were found to contain 0.13 U VIIIR:Ag/5 x 108 platelets. The patient's platelets also released VIIIR:Ag normally: 40% of total platelet VIIIR:Ag being released by collagen, 25% by thrombin, and 30% by ADP. The collagen and ADP-released VIIIR:Ag had the same electrophoretic characteristics as the VIIIR:Ag in the patient's plasma (Fig. 7) . Thus, compared to the VIIIR:Ag released by collagen and ADP from normal platelets, the slower migrating forms of VIIIR:Ag were depleted in this patient. The VIIIR:Ag released by thrombin was electrophoretically different from the patient's plasma VIIIR:Ag in that there was a still further depletion of slower migrating VIIIR:Ag forms (Fig. 7) . Thrombin-released VIIIR:Ag from normal platelets was also depleted of the slower migrating forms and did not differ from the patient's thrombin-released VIIIR:Ag. trophoretic mobility as compared to that released from normal platelets. Our results, with different methods of lysis, confirmed this observation and also provided additional observations. Freeze-thaw lysis of our patient's platelets released VIIIR:Ag significantly different from that released by freeze-thaw lysis of normal platelets. However, freeze-thaw lysis of normal platelets resulted in the release ofVIIIR:Ag which was depleted of the slower migrating forms compared to normal plasma (Fig. 6) . Freeze-thaw lysis of the patient's platelets, on the other hand, released VIIIR:Ag that was electrophoretically identical to her plasma VIIIR:Ag (Fig. 7) . In addition, we found that detergent lysis with Triton X-100 ofthe patient's platelets resulted in the release of slow migrating forms of VIIIR:Ag that were not present in her plasma (Fig. 7) . However, a similar phenomenon occurred with Triton X-100 lysis of normal platelets (Fig. 6 ) and the net effect was that the patient's Triton X-100-released VIIIR:Ag still lacked some of the slower migrating forms present in normal platelets.
DISCUSSION
A significant proportion of platelet-contained VIIIR:Ag appears to exist in a secretory pool which can be mobilized to varying degrees by ADP, collagen, and thrombin. Release of VIIIR:Ag by these agents is dependent on active metabolic processes within the platelets because it is markedly depressed by agents that inhibit the platelet's energy metabolism. This would indicate that VIIIR:Ag release is a true secretory reaction and not the result of some form of proteolytic digestion of platelet membrane-bound VIIIR:Ag. In support of this contention is the fact that, using the highly sensitive two-dimensional technique of radioimmunoelectrophoresis, no forms of released VIIIR:Ag could be detected with migration other than that found normally in plasma.
The method we used to wash platelets renders them relatively insensitive to ADP (35) washing was used to assure that the platelets were free of external VIIIR:Ag (36) . However, the concentrations of ADP necessary for VIII:Ag release were no greater than those necessary for serotonin release.
Although the data presented in this report does not give definitive information as to the nature of the VIIIR:Ag pool, the differences in the dose-response dynamics between VIIIR:Ag and both 5HT and lysosomal enzyme release and the differential effects of the metabolic inhibitors raises the possibility that VIIIR:Ag resides in a different pool from the dense granules and lysosomal enzyme-containing a-granules of the platelet.
The time-course pattern of VIIIR:Ag release is consistent with a single stimulatory event that induces a rapid initial release. As might be anticipated, the rate of these events progressively diminishes with time as a result of the depletion of available releasable material. The active metabolic processes initiated in platelets by ADP, collagen, or thrombin are thought to lead to the movement of storage granules to the platelet membrane and the fusion of the two (37) . Subsequent events, such as the movement of substances out of the granules and through the platelet canalicular system to the outside, are influenced by the diffusion constant of the molecules as well as possible interactions with the platelet surface. Diffusion constants of molecules are inversely proportional to size and it is not unexpected that VIIIR: Ag, with a molecular weight of up to 5 x 106 daltons, diffuses significantly more slowly than 5 HT or the lysosomal enzymes. There was a significant increase, with time, of the proportion of larger, more slowly migrating forms of VIIIR:Ag released. This suggests that molecular size and rate of release are correlated. Similarly, fibrinogen (340,000 mol wt) has a rate of release intermediate to VIIIR:Ag, on the one hand, and the lysosomal enzymes and 5HT on the other.
The electrophoretic characteristics of plateletderived VIIIR:Ag differed according to the techniques used to release it. ADP and collagen released VIIIR-Ag from platelets that were identical to the VIIIR:Ag in plasma. Thrombin-released VIIIR:Ag, however, was depleted of the slower migrating forms. Freeze-thaw lysis also led to the release ofVIIIR:Ag which was relatively depleted of the slower migrating forms, whereas lysis by the detergent Triton X-100 released proportionately more of these forms as compared to normal plasma.
These differences cannot be readily attributed to proteolysis. Purified VIIIR:Ag or collagen-released platelet VIIIR:Ag was not altered in its electrophoretic mobility by incubation with thrombin or collagenreleased platelet products, or material released from The results reported here show that platelet VIIIR:Ag is released by physiological concentrations of collagen, thrombin, and ADP. At sites of vascular damage, where platelets amass and undergo the release reaction, high concentrations of VIIIR:Ag will be made locally available. This platelet VIIIR:Ag supports platelet aggregation in the presence of ristocetin (6, 23) and binds to isolated platelet membranes.2 Thus, with respect to platelet function, platelet VIIIR:Ag has the same properties as plasma VIIIR:Ag. It is, therefore, reasonable to assume that platelet-released VIIIR:Ag makes an important contribution to the function of platelets during the primary hemostatic process.
